Replies to post #381123 on Innovation Pharmaceuticals Inc (IPIX)

[DrBones]

The difference is that Remdesivir is a failed drug against Hepatitis C and RSV. Brilacidin, on the other hand, has been successful against ABSSSI, OM, UP/UPS. It has proven mechanisms of action.

[frenchbroad]

*Lots of chickens being counted when the rooster is probably infertile.*

Lots of roosters losing their crow.

[thefamilyman]

Sunspotter said,

No, it doesn't. There are literally dozens of compounds that work excellently against COVID 19 in vitro, but don't work at all in vivo.

You did not address my point. Did any of those “dozens of compounds” work in vivo against ABSSSI? I didn’t think so. Brilacidin has already worked in vivo. My point stands.

Sunspotter said,

And there is remdesivir, with an SI of over 1000 (brilacidin is a mere 426) that has marginal efficacy at best.

And once again, that questionable 1000 SI number for Remdesivir was determined by Gilead employees. Cell Research says that Remdesivir’s real SI number is 129.87. Perhaps that’s why Remdesivir’s performance in the clinic is not as good as Gilead led the FDA to believe it would be when they filed for the EUA. The 426 SI number for Brilacidin was determined by independent testing at a US Regional Biocontainment Laboratory. So, which SI numbers are more likely to be accurate?